The Center for the Biology of Chronic Disease (CBCD) has recently released a study explaining how hidden viruses like cytomegalovirus (CMV) might contribute to an increased risk of premature death. This study, featured in the medical journal Antiviral Therapy, employs the microcompetition model to investigate why latent viruses such as CMV, EBV, HPV, and HSV, detected through a simple blood test, could be widespread and lead to health problems. Despite lacking clear symptoms, these viruses may silently contribute to organ failure, raising questions about why some individuals develop diseases related to latent viruses while others do not and why the onset of these diseases varies. The study suggests that the quantity of viral genomes in the body, known as the viral copy number, plays a crucial role, with higher numbers increasing the likelihood of developing a major disease sooner.

The research, led by Dr. Hanan Polansky, highlights the potential impact of latent viruses on health and lifespan for a significant portion of the population. The study proposes that controlling these latent viruses through treatments like Gene-Eden-VIR and Novirin could contribute to prolonging life and preventing major diseases. Clinical tests conducted by CBCD on these antiviral treatments showed effectiveness against various viruses, including HPV, HSV, CMV, and EBV, and the results were published in reputable peer-reviewed journals. In essence, this research underscores the importance of understanding and addressing latent viruses to improve overall health outcomes and potentially extend life expectancy.